Voyager Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.76 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 108.45M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Details
| Name | Voyager Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 141 |
| Founded | 2013 |
| Ipo Date | 2015-11-11 |
| Ceo | Alfred Sandrock |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US92915B1061 |
| Cusip | 92915B106 |
| Cik | 0001640266 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Trista Morrison | Chief Corporate Affairs Officer and Chief of Staff to the Chief Executive Officer |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder |
| Dr. Mark A. Kay M.D., Ph.D. | Founder |
| Amy Quinlan | Principal Accounting Officer |
| Todd Carter Ph.D. | Chief Scientific Officer |
| Dr. Mathieu Nonnenmacher Ph.D. | Vice President of Gene Therapy |
| Mihalis Kariolis | Vice President of Non-Viral Therapeutics |
Contact
| Address | 75 Hayden Avenue, Lexington, Massachusetts 02421, United States |
| Phone | 857 259 5340 |
| Website | https://www.voyagertherapeutics.com |